CAC
CERE

Cowen and Company’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Cowen and Company’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-200,000
Closed -$287K – 765
2024
Q2 		$287K Buy
+200,000
New +$8.33M 0.01% 199

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Cowen and Company's CERE Position: Q4 2020 in Review

Cowen and Company sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q4 2020, closing a stake of 14,000 shares — an estimated $146K sold.

Cowen and Company first reported a position in CERE in Q3 2020 and held it in 1 quarter. The position peaked at $146K in Q3 2020. 58 funds tracked by Wall St. Rank hold CERE as of Q4 2020.

  • Cowen and Company reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Cowen and Company sold 14,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q4 2020, an estimated $146K.
  • Cowen and Company first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Cowen and Company's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $146K in Q3 2020.
  • 58 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q4 2020.

Based on Cowen and Company's 13F filing for Q4 2020, filed 8 Feb 2021.